**Abstract**

***Background:*** Clinical studies show that ketamine, an NMDA receptor antagonist, produces a rapid and sustained antidepressant response, while classical antidepressants require repeated treatment for up to four weeks to produce similar effects^1^. Due to the high number of individuals with affective disorders, which are resistant to the established monoaminergic drug therapies, there is a great need to develop novel and more effective antidepressants^1^. Ketamine has a potential to be applied as an alternative intervention to patients with treatment resistant depression^2^, but given methodological difficulties there are only few studies evaluating its effects in adequate animal models.

***Aims:*** This project aims to assess whether systemic treatment with ketamine may improve the behavioural response in an animal model of a treatment resistant condition.

***Methods:*** Male Sprague-Dawley rats received subcutaneous injections of ACTH (100ug/rat/day) or vehicle during 14 days. On the 14^th^ day the animals were exposed to the pre-test session of forced swim (FST) and after 24h they were exposed to the open-field test (OFT) followed by the FST test session. The animals received an intraperitoneal injection of ketamine (15 mg/kg) or vehicle or imipramine (3 injections of 15 mg/kg) 1h before the test session.

***Results:*** The immobility time during the pre-test was increased on the group treated with ACTH (F~(14,37)~=3,484; \*p\<0,05; Dunnett). Ketamine, but not imipramine, reduced the immobility time when exposed to the test session (F~(2,16)~=4,002; \*p\<0,05; Dunnett). The OFT showed that the drugs did not increase the locomotor activity.

***Conclusion:*** The data suggest that ACTH treatment can induce a pro-depressive-like effect, which highlights its role as an inducer of a treatment-resistant condition. The results reinforce the potential antidepressant-like effects of ketamine in a treatment resistant condition, thus corroborating the literature findings. Further studies are necessary to investigate the mechanisms which ketamine induces its effects on treatment resistant rats.
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